Clemens J D, Ferreccio C, Levine M M, Horwitz I, Rao M R, Edwards K M, Fritzell B
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore.
JAMA. 1992 Feb 5;267(5):673-8.
To assess whether serum antibody responses to diphtheria-tetanus-pertussis (DTP) vaccine were affected by coadministration of Haemophilus influenzae type b capsular polyribosylribitol phosphate polysaccharide-tetanus protein (PRP-T) conjugate vaccine when given to patients at 2, 4, and 6 months of age.
Randomized, double-blind clinical trial.
Urban Santiago, Chile.
Healthy infants assembled from health centers. Two hundred seventy-eight (74%) of 375 eligible infants participated; 222, who complied with the complete protocol, constituted the primary group under analysis.
One of three vaccine regimens was given to study participants at 2, 4, and 6 months of age, either DTP mixed in the same syringe as PRP-T (group 1); DTP and PRP-T given at separate injection sites (group 2); or DTP without PRP-T (group 3).
Titers of serum antidiphtheria toxoid, antitetanus toxoid, and pertussis agglutinin antibodies were measured in blood samples taken from patients 2 months after each dose.
Serum antidiphtheria toxoid and antitetanus toxoid responses showed no important depressions in the patients receiving PRP-T. In contrast, geometric mean titers (GMTs) of pertussis agglutinins, expressed as reciprocal serum dilutions, after both the second and third doses (GMT2, GMT3) were lowest in group 1 (GMT2 = 89; GMT3 = 1230), intermediate in group 2 (GMT2 = 123; GMT3 = 1995), and highest in group 3 (GMT2 = 210; GMT3 = 3090; P less than .05 for trend group 1 less than group 2 less than group 3 after each dose). Antipertussis toxin and antipertussis filamentous hemagglutinin antibody titers also were depressed in patients who received PRP-T. Follow-up of a subset at 18 months revealed an expected decline of pertussis agglutinin titers to near baseline levels in each group.
Concurrent administration of PRP-T vaccine with DTP vaccine, either in the same syringe or at different sites, interfered with antipertussis responses to a primary series of immunizations. Although the clinical significance of this antagonism is uncertain, these data underscore the caution required in decisions to add new vaccines to existing immunization regimens.
评估在2、4和6月龄的患者中,给予b型流感嗜血杆菌结合疫苗(PRP-T)时,白喉-破伤风-百日咳(DTP)疫苗的血清抗体反应是否受到影响。
随机、双盲临床试验。
智利圣地亚哥市。
从健康中心招募的健康婴儿。375名符合条件的婴儿中有278名(74%)参与;222名符合完整方案的婴儿构成主要分析组。
在2、4和6月龄时,对研究参与者给予三种疫苗方案之一,即DTP与PRP-T混合在同一注射器中(第1组);DTP和PRP-T在不同注射部位给予(第2组);或仅给予DTP(第3组)。
在每次给药后2个月采集的血样中,检测血清抗白喉类毒素、抗破伤风类毒素和百日咳凝集素抗体的滴度。
接受PRP-T的患者血清抗白喉类毒素和抗破伤风类毒素反应无明显降低。相比之下,第2剂和第3剂后百日咳凝集素的几何平均滴度(GMTs,以血清稀释倍数的倒数表示)在第1组最低(GMT2 = 89;GMT3 = 1230),第2组中等(GMT2 = 123;GMT3 = 1995),第3组最高(GMT2 = 210;GMT3 = 3090;每次给药后第1组<第2组<第3组的趋势P<0.05)。接受PRP-T的患者抗百日咳毒素和抗百日咳丝状血凝素抗体滴度也降低。对一个亚组在18个月时的随访显示,每组百日咳凝集素滴度预期下降至接近基线水平。
PRP-T疫苗与DTP疫苗同时接种,无论是在同一注射器中还是在不同部位,都会干扰初次免疫系列的抗百日咳反应。尽管这种拮抗作用的临床意义尚不确定,但这些数据强调了在决定将新疫苗添加到现有免疫方案中时需要谨慎。